search icon
  • Print
  • ShareThis
  • Text Size

RSS Feed Print Category View
AbbVie steps closer to FDA filing as first hep C PhIII delivers promising results
tkim@idsociety.org
Posted: Monday, November 18, 2013 1:45 PM
Joined: 2/20/2013
Posts: 39


"AbbVie's all-oral "3D" regimen scored high sustained virological response rates among 631 treatment-naive patients after 12 weeks of treatment, hitting 96% for the treatment arm. The patients were all in the hard-to-treat genotype 1 category, with SVR rates of 95% and 98% for GT1a and GT1b patients. The discontinuation rate was low, only 0.6%, with a 1.7% relapse rate."

To read more, please visit: http://www.fiercebiotech.com/story/abbvie-steps-closer-fda-filing-first-hep-c-phiii-delivers-stellar-results/2013-11-18?utm_medium=nl&utm_source=internal
 

| HIVMA | Contact Us

© Copyright IDSA 2014 Infectious Diseases Society of America

Full Site Mobile Site